Patent: 10,730,880
Summary for Patent: 10,730,880
| Title: | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors |
| Abstract: | Compounds of Formula I: ##STR00001## and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities. |
| Inventor(s): | Allen; Shelley (Boulder, CO), Boys; Mark Laurence (Boulder, CO), Chicarelli; Mark J. (Boulder, CO), Fell; Jay Bradford (Boulder, CO), Fischer; John P. (Boulder, CO), Gaudino; John (Boulder, CO), Hicken; Erik James (Boulder, CO), Hinklin; Ronald Jay (Boulder, CO), Kraser; Christopher F. (Boulder, CO), Laird; Ellen (Boulder, CO), Robinson; John E. (Boulder, CO), Tang; Tony P. (Boulder, CO), Burgess; Laurence E. (Boulder, CO), Rieger; Robert Andrew (Boulder, CO), Pheneger; Jed (Boulder, CO), Satoh; Yoshitaka (Poway, CA), Leftheris; Katerina (San Diego, CA), Raheja; Raj K. (Poway, CA), Bennett; Brydon L. (San Diego, CA) |
| Assignee: | Array BioPharma Inc. (Boulder, CO) Celgene Corporation (Summit, NJ) |
| Application Number: | 16/212,493 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,730,880
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Pharmacia & Upjohn Company Llc | ATGAM | lymphocyte immune globulin, anti-thymocyte globulin (equine) | Injection | 103676 | December 4, 1996 | 10,730,880 | 2038-12-06 |
| Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | December 10, 1997 | 10,730,880 | 2038-12-06 |
| Bristol-myers Squibb Company | ORENCIA | abatacept | For Injection | 125118 | December 23, 2005 | 10,730,880 | 2038-12-06 |
| Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | July 29, 2011 | 10,730,880 | 2038-12-06 |
| Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | June 7, 2016 | 10,730,880 | 2038-12-06 |
| Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | March 30, 2017 | 10,730,880 | 2038-12-06 |
| Biogen Inc. | ZINBRYTA | daclizumab | Injection | 761029 | May 27, 2016 | 10,730,880 | 2038-12-06 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
